---
run_id: halo-evidence-vs-diagnosis-validation-v11-generic-advice-prompted-08
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: generic_advice_prompted
run_number: 8
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 805
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
condition_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
output_file: model-outputs/generic_advice_prompted-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `generic_advice_prompted`, run 8 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 805, on the frozen condition packet.

## Output

### Recommendation: Run the Claim File Review

I recommend you commit to the **Claim File Review**.

#### Reasoning
You are currently facing a "false positive" crisis. Your lagging indicators (expansion bookings, renewals) are being skewed by pricing incentives and sales narratives, while your leading indicators (usage) are being skewed by "vanity" activity from managers rather than utility for the end-user.

The most dangerous signal in your data is the **behavioral decay** of front-line adjusters (heavy use for two days, then abandonment) and the **explainability gap** in health-liability. This suggests that SignalPath may be "demo-ware"—impressive to a buyer or a manager, but friction-heavy for the practitioner.

Here is why the other options are insufficient or risky:
*   **Scale Broadly:** This is reckless. You have evidence of silent churn (the regional carriers) and a lack of product-market fit in regulated segments. Scaling now would likely increase churn in 6–12 months.
*   **Usage Quality Sprint:** This measures *if* people are using it, but not *why* they stop. You already know the return rate is low; more dashboards won't tell you if the recommendations are wrong or simply unexplainable to a reviewer.
*   **Commercial Cleanroom:** This tests the *sales pitch*, not the *product*. If you find that buyers don't buy without the roadmap pitch, you still won't know if the product actually solves the problem once installed.
*   **Narrow to Health-Liability:** This is a premature pivot. You have evidence that this segment specifically struggles with the product; narrowing your focus to the most difficult segment before fixing the core utility is a strategic error.

The **Claim File Review** is the only option that provides "ground truth." By auditing actual files, you move from *quantitative* usage (which is currently misleading) to *qualitative* utility. You will discover if the "abandonment" is due to bad logic, poor UI, or regulatory constraints. This is the only data set that can inform whether you need to pivot the product's logic or simply improve the enablement.

#### The Trade-offs
By choosing the Claim File Review, you are sacrificing **speed of commercial validation**. You will not have a "clean" sales experiment (the Cleanroom) to tell the board exactly how much revenue is tied to the bundle pricing. You are accepting a period of uncertainty regarding the immediate quarterly bookings in exchange for certainty regarding long-term product viability.

#### The Strongest Reason Against This Recommendation
The Claim File Review is slow and manually intensive. In a high-pressure environment with a board deadline in twelve days, the executive team may perceive this as "academic" or "too slow." It does not provide a binary "yes/no" on revenue growth for the next quarter; it provides a diagnosis of product health. There is a risk that by the time the review is complete, you have missed the window to adjust your sales strategy for the upcoming renewal cycle.

#### Observable Evidence That Would Change My Mind
I would switch my recommendation to the **Commercial Cleanroom** if you discovered that the "silent churn" from the regional carriers was not due to product utility, but specifically due to a pricing misalignment (e.g., they love the tool but find the bundle price structure offensive). If the problem is *pricing* rather than *product-market fit*, diagnosing the file utility is a waste of time; you would need to fix the commercial model immediately to stop the bleeding.
